The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature
This case implies that in patients with hepatocellular carcinoma who have failed first-line targeted therapy and ICIs, targeted therapy and ICIs can be restarted with the addition of lenalidomide, with surprising results.
Authors
- Keren Li (ORCID: https://orcid.org/0000-0001-5559-0421)
- Tao Li (ORCID: https://orcid.org/0000-0002-7988-3090)
- Guangxin Li (ORCID: https://orcid.org/0000-0003-2524-0556)
- Ying Zhao (ORCID: https://orcid.org/0000-0003-3965-4872)
- Gong Li
Institutions
- Beijing Tsinghua Chang Gung Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fonc.2024.1461936
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00